These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 34717577

  • 1. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
    Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Nihonmatsu H, Hara K, Chuma M, Tsurugai Y, Maeda S.
    BMC Cancer; 2021 Oct 30; 21(1):1169. PubMed ID: 34717577
    [Abstract] [Full Text] [Related]

  • 2. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R, Kay CS, Heo SJ, Won JY, Seong J.
    J Hepatol; 2020 Jul 30; 73(1):121-129. PubMed ID: 32165253
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.
    Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Hara K, Chuma M, Eriguchi T, Tsurugai Y, Maeda S.
    PLoS One; 2021 Jul 30; 16(1):e0245076. PubMed ID: 33400718
    [Abstract] [Full Text] [Related]

  • 4. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y, Cao Y, Ma H, Kan X, Zhou C, Liu J, Shi Q, Feng G, Xiong B, Zheng C.
    BMC Cancer; 2019 Oct 22; 19(1):983. PubMed ID: 31640620
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR, Park E, Kwon SY, Park SJ, Kim YJ, Yoo BC, Choe WH, Kim JH, Hwang JH, Park SW, Kim YJ, Park HS, Yu MH, Jeon HJ.
    Korean J Gastroenterol; 2019 Mar 25; 73(3):167-176. PubMed ID: 31013560
    [Abstract] [Full Text] [Related]

  • 6. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O.
    Strahlenther Onkol; 2019 Mar 25; 195(3):254-264. PubMed ID: 30413833
    [Abstract] [Full Text] [Related]

  • 7. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
    Lee S, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Kim JM, Kim K.
    J Hepatol; 2018 Jul 25; 69(1):70-78. PubMed ID: 29524532
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY, Lee Y, McLean K, Leggett D, Hodgkinson P, Fawcett J, Mott R, Stuart K, Pryor D.
    Clin Oncol (R Coll Radiol); 2020 Oct 25; 32(10):e194-e202. PubMed ID: 32345457
    [Abstract] [Full Text] [Related]

  • 9. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
    Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J.
    Radiother Oncol; 2019 Feb 25; 131():81-87. PubMed ID: 30773192
    [Abstract] [Full Text] [Related]

  • 10. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.
    Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung TT, Chiang CL, Wong TCL, Kong FM, Wu G, Lo CM.
    Medicine (Baltimore); 2022 Jan 28; 101(4):e28545. PubMed ID: 35089192
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
    Feng X, Xu R, Du X, Dou K, Qin X, Xu J, Jia W, Wang Z, Zhao H, Yang S, Guo C, Liu T, Ma K.
    Am J Gastroenterol; 2014 Dec 28; 109(12):1891-9. PubMed ID: 25403366
    [Abstract] [Full Text] [Related]

  • 15. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
    Hirooka M, Hiraoka A, Ochi H, Kisaka Y, Joko K, Michitaka K, Hiasa Y.
    AJR Am J Roentgenol; 2018 Apr 28; 210(4):891-898. PubMed ID: 29412017
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A).
    Lee H, Yoon CJ, Seong NJ, Jeong SH, Kim JW.
    Korean J Radiol; 2018 Apr 28; 19(6):1130-1139. PubMed ID: 30386144
    [Abstract] [Full Text] [Related]

  • 17. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW, Chen YS, Lo GH, Hsu YC, Hsu CC, Wu TC, Yeh JH, Hsiao P, Hsieh PM, Lin HY, Shu CW, Hung CM.
    BMC Gastroenterol; 2020 Apr 10; 20(1):99. PubMed ID: 32272898
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
    Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M.
    J Clin Oncol; 2016 Feb 10; 34(5):452-9. PubMed ID: 26628466
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study.
    Lassandro G, Picchi SG, Bianco A, Di Costanzo G, Coppola A, Ierardi AM, Lassandro F.
    Med Oncol; 2020 Mar 12; 37(4):25. PubMed ID: 32166529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.